Patents by Inventor Liselotte Langkjaer

Liselotte Langkjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of insulin
    Patent number: 7387996
    Abstract: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: June 17, 2008
    Assignee: Novo Nordisk A/S
    Inventor: Liselotte Langkjaer
  • Novel formulations
    Publication number: 20070155654
    Abstract: Stable, soluble insulin formulations having both a fast and a long action.
    Type: Application
    Filed: February 1, 2007
    Publication date: July 5, 2007
    Applicant: Novo Nordisk A/S
    Inventor: Liselotte Langkjaer
  • Novel formulations
    Publication number: 20050261168
    Abstract: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.
    Type: Application
    Filed: July 29, 2005
    Publication date: November 24, 2005
    Inventor: Liselotte Langkjaer
  • Novel formulations
    Publication number: 20040006000
    Abstract: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.
    Type: Application
    Filed: May 5, 2003
    Publication date: January 8, 2004
    Inventor: Liselotte Langkjaer
  • Novel formulations
    Publication number: 20030232748
    Abstract: Stable, soluble insulin formulations having both a fast and a long action.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 18, 2003
    Inventor: Liselotte Langkjaer
  • Novel insulin peptides
    Patent number: 5008241
    Abstract: Insulin analogs characterized by amino acid residue at A21 other than Asn, with a resulting improvement in stability of insulin solutions at acid pH levels. Some insulin analogs may also have amino acid residue changes elsewhere so that these insulin analogs exhibit at least about one charge more than human insulin at a pH value of 7, with preferred substitutions being made for the glutamic acid residues at A4, A17, B13, B21 and/or a basic amino acid residue being substituted at B27. Also contemplated is optional blocking the C-terminal carboxyl group of the B-chain with an amido or ester residue.
    Type: Grant
    Filed: October 20, 1989
    Date of Patent: April 16, 1991
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Kjeld Norris, Liselotte Langkjaer